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at further risk from untreated imported material. We appreciate the
possible risk to families or health-care attendants of exposure to
these products but would regard these risks as very small when
compared with the danger of concomitant blood exposure and
would reinforce the need for extreme care during administration.
The continued use of non-heated British concentrate will not
compromise the aim of national self sufficiency of factor VIII. All
patients receiving heat-treated preparations must be thoroughly
monitored for appearance of reactions and formation of factor VIII
antibodies and results compared with those in the non-heat-treated
cohort.
The urgency of the situation must not be allowed to obscure the
need for a clearly defined policy for the future, formed on scientific
evidence, and for management to be based on serological status.
Hasty and ill-considered decisions may expose haemophiliacs to
new and further risks and may foster complacency which could
delay the implementation of measures required now to slow
transmission of the virus and to protect the remaining vulnerable
members of at-risk groups.
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SULPHADIAZINE DESENSITISATION IN AIDS
PATIENTS
SiR,-Adverse reactions to sulphonamides in AIDS patientsl,2
may become especially troublesome in the treatment of cerebral
toxoplasmosis where regimens lacking sulphonamides are not
effective. Successful desensitisation has been demonstrated in
patients with inflammatory bowel disease 3-6 but not, to our
knowledge, in AIDS patients. We describe here successful
desensitisation to sulphadiazine in three AIDS patients with
cerebral toxoplasmosis who had had severe sulphonamide reactions.
The patients, all male homosexuals, had AIDS diagnosed on the
basis of biopsy-proven cerebral toxoplasmosis (one) and
Pneumocystis carinii pneumonia (two). The latter two patients later
had cerebral abscesses compatible with toxoplasmosis on
computerised tomographic scanning which regressed completely
on anti-toxoplasma therapy. All three patients had fever (more than
39-4&deg;C), leucopenia (below 1500/1), and a diffuse maculopapular
rash during sulphonamide therapy for toxoplasmosis; two patients
were also on dexamethasone 16 mg daily for increased intracranial
pressure. Two patients had similar reactions to co-trimoxazole for
P carinii pneumonia.
Before desensitisation, each patient was maintained on
dexamethasone (9-16 mg daily). Sulphadiazine was then started at a
dose of 250 mg daily in conjunction with pyrimethamine 25 mg
daily. The sulphadiazine dose was then increased by 250 mg every
second or third day. At daily doses of 1 - 5-2 - 0 g larger increments of
0-5-1-0 0 g every 1-2 days were well tolerated. Maximum daily
dosage achieved was 2 g in one patient and 4 g in two patients. Side-
effects included transient fever (less than 37’ 8&deg;C) in two patients,
mild pruritus in one patient, and hyperglycaemia in two patients,
presumably exacerbated by the steroids. Two patients noted a flare
of their rash when dexamethasone was reduced below 4 mg daily;
this was controlled by a brief increase in the dexamethasone dose in
one patient and by a reduction of the sulphadiazine dose to 2 g daily
in the other.
Cytomegalovirus retinitis was diagnosed in two patients 4 and 6
months after desensitisation. Whether this was promoted by the use
of steroids is unclear, though no exacerbation of other opportunistic
infections was noted. One patient remains alive 9 months after
desensitisation with complete resolution of cerebral lesions and has
tolerated a further reduction of dexamethasone to 1’ 5 mg daily.
Two patients died, 1 V2 and 7 months after desensitisation, of
unknown causes; the latter patient had resolution of cerebral
abscesses documented by CT scan.
Sulphadiazine desensitisation seems feasible in AIDS patients
experiencing severe sulphonamide reactions during therapy for
toxoplasmosis. Although Luft et al8 have suggested that
pyrimethamine, alone or with clindamycin or spiramycin, might be
used in these patients, we noted progression of cerebral lesions in
one patient treated with pyrimethamine and clindamycin and
believe that sulphadiazine desensitisation may offer a useful
alternative.
Section of Infectious Diseases,
Lenox Hill Hospital,
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RESPONSE OF MOYAMOYA DISEASE TO VERAPAMIL
SIR,-Moyamoya disease is a vaso-occlusive disease of the
intracranial circulation that is seldom seen in Western countries.
The cause is unknown. The disease is characterised by occlusion of
the intracranial internal carotid arteries and cerebral arteries, and it
gets its name from the anastomotic networks seen on the angiogram
(the Japanese word moyamoya means "puff of smoke").l The
clinical course in children varies but often results in a chronic
dependency.z This gloomy outlook and the uncertain success of
surgery justify the search for different treatments. Clinical reports
in other conditions suggest that calcium antagonists might be useful
in moyamoya disease. For example, morbidity and mortality in
patients with subarachnoid haemorrhage may have been reduced by
nimodipine,3 calcium antagonists had prophylactic value in
treatment of migraine, 4-6 and alternating hemiplegia in children has
been reported to improve during therapy with flunarizine. 
7
Case 1
This 6-year-old white girl with a history of seizures (with postictal
stupor and right arm weakness) controlled by carbamazepine was
admitted with progressive right hemiparesis and mutism.
Angiography revealed transbasal and transmeningeal anastomoses
typical of moyamoya disease. After a left superficial temporal to
middle cerebral artery graft and synangiosis with a patch ofdura and
muscle her right arm remained slightly weak. At the age of 6 years 8
months she had a mental age of 2 years 7 months and was severely
aphasic.
Seizures recurred 11 months after surgery and she became mute
with a right hemiparesis. She was brought to hospital with the right
arm held flexed at the waist and the thumb in fist. She did not use the
arm and walked clumsily. There was right hypotonia with
hyperreflexia and ankle clonus, but no Babinski sign. She could not
understand (or obey) simple commands. Verapamil 10 mg was
administered intravenously over 5-10 min without adverse effect.
10 min later the child spoke several simple sentences, grasped the
drip stand with her right hand, and walked with minimal
circumduction on command.
Computerised tomography revealed loss of substance in the
perisylvian region bilaterally and over the superior right frontal
convexity, and enlargement of the ventricular system. With the
informed consent of the parents, the effect of verapamil was
investigated angiographically under general anaesthesia. Serial
synchronised biplane cerebral angiograms were obtained after left
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Effect of intravenous verapamil on cerebral vasculature of child with
moyamoya disease.
Upper: lateral subtraction angiogram (left common carotid injection) before
verapamil, at high resolution to emphasise transbasal collaterals.
Lower: after verapamil, phase being matched with that of upper picture.
Note augmented filling of the transbasal collaterals and the increased
dimensions of anastomotic network (double asterisks), suggesting
opacification of "new vessels". Calibre of posterior branch of middle cerebral
artery is increased (double arrows), suggesting vasodilatation. Filling of left
anterior cerebral artery through transbasal anastomoses appears to be
enhanced (triple arrows).
common carotid injection of 5 ml of 60% meglumine iothalamate
before and 10 min after intravenous administration of 10 mg
verapamil. Some vessels in the region of the left basal ganglia and a
posterior cerebral vessel appeared to be increased in calibre (figure)
after verapamil. There were no complications and subsequently oral
verapamil was started. The child did not improve beyond her
condition before the most recent episode. During 18 months of oral
therapy with verapamil (20 mg three times daily) no further
neurological deficits have developed.
Case 2
This 3-year-old white boy had a history of focal seizures at age 11
months after which he uttered only grunts and switched to using his
left hand. He had then been seizure-free for a year while taking
phenobarbitone, and language improved. At the age of 2 he had an
episode of lethargy and vomiting followed by focal right facial
seizures. 16 months later he became fatigued over several weeks,
vomited, and had tonic-clonic seizures followed by mutism and
difficulty in swallowing. He switched back to right-handedness. A
slight left facial and arm paresis persisted.
Computerised tomography revealed right hemispheric loss of
substance. The posterior cerebral and internal carotid arteries were
occluded (with redirected flow) and transdural and transmeningeal
anastomoses were noted. 3 months after bypass surgery (as in case 1)
his vocabulary had increased but a mild left hemiparesis persisted
and he reverted to left-handedness.
At age 6% he was admitted with a severe headache and left facial
paresis. Shortly after intravenous administration of verapamil
(10 mg over 5 min) the headache diminished, and by 60 min the
facial paresis had resolved. 5 months later resolution of the acute
deficit has persisted.
These two cases suggest that acute neurological deficits due to
moyamoya disease may be improved by treatment with the calcium
antagonist verapamil. In case 1 the deficits, progressive over one
week and preceded by seizures, were consistent with a slow vaso-
occlusive process. The increased perfusion through transbasal
anastomoses (figure) suggested that verapamil acted by reversal of
vasospasm. In case 2 the headache and facial paresis mimicked
complicated migraine and could also be explained by vasospasm.
Controlled studies, bearing in mind the possibility of adverse effects
such as systemic hypotension with decreased cerebral perfusion and
over-distension of abnormally fragile moyamoya blood vessels with
resultant haemorrhage, are now needed. Clinicians in countries
where moyamoya disease is more prevalent will be better placed to
do these.
We thank Dr Dale Singer for her assistance with case 2, and Ms Debbra L.
Neuvirth for secretarial help.
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CSF CONCENTRATIONS OF RANITIDINE
SIR,-Cimetidine but not oxmetidine can be detected in the
cerebrospinal fluid (CSF) in small amounts after a single intra-
venous dosel and after one week of oral medication at therapeutic
doses.2 Case-reports of mental confusion after treatment with
ranitidine have been published 3-6 so measurement of CSF
ranitidine concentrations may be valuable.
Ten patients scheduled for diagnostic lumbar puncture volun-
teered to take 150 mg ranitidine twice daily for six days. On the
morning of the seventh day 150 mg was given and lumbar puncture
was done 2 h, 4 h, or 6 h later. Blood samples were taken before the
morning dose on day 7 and at the same time as the lumbar puncture.
Venous blood and CSF were analysed for ranitidine by an assay
detecting 4 ng/ml or more.
Ranitidine was detected in the CSF in all ten patients (table).
The CSF/plasma ratio was 0 - 08, 0 - 06, and 0 17 at 2, 4, or 6 h. The
higher ratio in the 6 h samples can be ascribed to the lower plasma
concentrations at that time. CSF/blood albumin ratios were used to
define the status of the blood-brain barrier in each patient. One
patient (a 75-year-old woman) had a defective blood-brain barrier
but her ranitidine CSF/plasma ratio was 0 - 08, only slightly above
the mean (0’ 06). No patient showed signs of mental confusion while
taking ranitidine.
Although the CSF concentration of ranitidine is lower than the
corresponding CSF concentration of cimetidine (mean 0 10 j-tg/ml
plus 0-07 fg/ml for cimetidine’s sulphoxide metabolite),2 the
CSF/plasma ratios of the drugs are almost equal-namely, 0 - 06 for
ranitidine and 0 - 07 for cimetidine.
The mental confusion seen in the occasional patient treated with
cimetidine or ranitidine is unexplained. In two cases mental con-
fusion developing in a patient on cimetidine did not recur when the
patient took ranitidine. 7 However, in one case ranitidine was
given at a pharmacologically lower dose than cimetidine, though
both drugs were given at doses higher than normally recommended.
In the other cases cimetidine was given in a high intravenous dose
despite depressed renal function. When mental confusion appeared
